[go: up one dir, main page]

PE20081507A1 - Derivados de pirimidina como moduladores de jnk - Google Patents

Derivados de pirimidina como moduladores de jnk

Info

Publication number
PE20081507A1
PE20081507A1 PE2007001744A PE2007001744A PE20081507A1 PE 20081507 A1 PE20081507 A1 PE 20081507A1 PE 2007001744 A PE2007001744 A PE 2007001744A PE 2007001744 A PE2007001744 A PE 2007001744A PE 20081507 A1 PE20081507 A1 PE 20081507A1
Authority
PE
Peru
Prior art keywords
pyrimidin
alkyl
ilamino
indol
halogen
Prior art date
Application number
PE2007001744A
Other languages
English (en)
Inventor
James Patrick Dunn
David Michael Goldstein
Leyi Gong
Joan Heather Hogg
Christophe Michoud
Wylie Solang Palmer
Achyutharao Sidduri
Tania Silva
Parcharee Tivitmahaisoon
Teresa Alejandra Trejo-Martin
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39099641&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20081507(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20081507A1 publication Critical patent/PE20081507A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

REFERIDA A UN DERIVADO DE PIRIMIDINA DE FORMULA (I), DONDE X1 ES N, N-R3, CH3, C-R3, O; X2 ES N, NH, N-CH3, CH, CH2, ENTRE OTROS; X3 ES N, C O CH; X4 Y X5 SON C, CH O N; R ES -(CICLOHEXIL)-R2 O -(FENIL)-R8 SUSTITUIDOS OPCIONALMENTE CON METILO, FLUOR, CLORO O HIDROXI; R1 ES HALOGENO, NITRO, CN, OH, ENTRE OTROS; n ES UN ENTERO DE 0 A 2; R3 ES H O ALQUILO C1-C6; R2 ES H, OH, =O, CN, ENTRE OTROS; R8 ES H, ALQUILO C1-C6, OR3, SO2NH2, ENTRE OTROS; Z ES H, HALOGENO, ALQUILO C1-C12, NH2. SON COMPUESTOS PREFERIDOS: 4-[4-(4-BENCILOXI-INDOL-1-IL)-PIRIMIDIN-2-ILAMINO]-CICLOHEXA-NOL, 4-[4-(4-BROMOINDOL-1-IL)-PIRIMIDIN-2-ILAMINO]-CICLOHEXANOL, (2-METANOSULFONILETIL)AMIDA DEL ACIDO 4-(4-INDOL-1-IL)-PIRIMIDIN-2-ILAMINO]-CICLOHEXANOCARBOXILICO, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA Y A UN PROCESO DE PREPARACION. DICHOS COMPUESTOS SON MODULADORES DE QUINASAS C-JUN-N-TERMINALES (JNK) Y SON UTILES EN EL TRATAMIENTO DE TRASTORNOS INMUNES, INFLAMATORIOS, NEUROLOGICAS, ENTRE OTRAS
PE2007001744A 2006-12-08 2007-12-07 Derivados de pirimidina como moduladores de jnk PE20081507A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87362506P 2006-12-08 2006-12-08

Publications (1)

Publication Number Publication Date
PE20081507A1 true PE20081507A1 (es) 2008-11-12

Family

ID=39099641

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001744A PE20081507A1 (es) 2006-12-08 2007-12-07 Derivados de pirimidina como moduladores de jnk

Country Status (18)

Country Link
US (1) US8399462B2 (es)
EP (1) EP2102194A1 (es)
JP (1) JP5179509B2 (es)
KR (1) KR101152162B1 (es)
CN (1) CN101547917A (es)
AR (1) AR064133A1 (es)
AU (1) AU2007328981B2 (es)
BR (1) BRPI0720003A2 (es)
CA (1) CA2670375A1 (es)
CL (1) CL2007003502A1 (es)
IL (1) IL198543A0 (es)
MX (1) MX2009005508A (es)
NO (1) NO20091942L (es)
PE (1) PE20081507A1 (es)
RU (1) RU2493155C2 (es)
TW (1) TW200831101A (es)
WO (1) WO2008068171A1 (es)
ZA (1) ZA200903495B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010529973A (ja) 2007-06-15 2010-09-02 エフ．ホフマン−ラ ロシュ アーゲー ３−アミノ−ペンタン−１，５−ジオールの新規製造方法
JP5587193B2 (ja) * 2007-10-23 2014-09-10 エフ．ホフマン−ラ ロシュ アーゲー 新規なキナーゼ阻害剤
EP2283009B1 (en) 2008-05-16 2012-08-29 F. Hoffmann-La Roche AG Inhibitors of jnk
CN102256965A (zh) * 2008-12-19 2011-11-23 霍夫曼-拉罗奇有限公司 嘧啶-2-基氨基衍生物和它们治疗炎症的用途
ES2525756T3 (es) * 2009-02-24 2014-12-30 F. Hoffmann-La Roche Ag Imidazo [1,2-a] piridinas como moduladores de JNK
EP2440058A4 (en) 2009-06-12 2012-11-21 Dana Farber Cancer Inst Inc MELTED HETEROCYCLIC COMPOUNDS AND APPLICATIONS THEREOF
JP5784604B2 (ja) * 2009-08-10 2015-09-24 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｊｎｋ阻害剤
EP2498607B1 (en) * 2009-11-13 2016-02-17 Genosco Kinase inhibitors
AU2010343102B2 (en) 2009-12-29 2016-03-24 Dana-Farber Cancer Institute, Inc. Type II Raf kinase inhibitors
CN102918035B (zh) * 2010-06-04 2015-05-27 霍夫曼-拉罗奇有限公司 用作jnk的抑制剂的2-氨基-嘧啶衍生物
RU2012155144A (ru) * 2010-06-04 2014-07-20 Ф. Хоффманн-Ля Рош Аг Ингибиторы jnk
CA2826295C (en) 2011-02-04 2020-10-20 Duquesne University Of The Holy Spirit Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity and methods of treating a patient
TR201807311T4 (tr) 2011-03-10 2018-06-21 Daiichi Sankyo Co Ltd Dispiropirolidin derivesi.
JP6106685B2 (ja) * 2011-11-17 2017-04-05 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド Ｃ−ｊｕｎ−ｎ−末端キナーゼ（ｊｎｋ）の阻害剤
EP2903440B1 (de) 2012-10-02 2017-09-06 Bayer CropScience AG Heterocyclische verbindungen als schädlingsbekämpfungsmittel
US10112927B2 (en) 2012-10-18 2018-10-30 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
WO2014063061A1 (en) 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
WO2014063054A1 (en) 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof
WO2014134776A1 (en) 2013-03-04 2014-09-12 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
WO2014134774A1 (en) 2013-03-04 2014-09-12 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
US9440952B2 (en) 2013-03-04 2016-09-13 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
WO2014134772A1 (en) 2013-03-04 2014-09-12 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
EP3057956B1 (en) 2013-10-18 2021-05-05 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7)
EP3057955B1 (en) 2013-10-18 2018-04-11 Syros Pharmaceuticals, Inc. Heteroaromatic compounds useful for the treatment of prolferative diseases
WO2015073344A1 (en) * 2013-11-14 2015-05-21 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
DK3126352T3 (en) 2014-04-04 2019-01-21 Syros Pharmaceuticals Inc CYCLINE INDEPENDENT KINASE 7 INHIBITORS (CDK7)
WO2015164614A1 (en) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
US9862688B2 (en) 2014-04-23 2018-01-09 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
EP3190889B1 (en) 2014-09-03 2021-11-17 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
SG10201909060SA (en) * 2014-12-11 2019-11-28 Beta Pharma Inc Substituted 2-anilinopyrimidine derivatives as egfr modulators
CA2972239A1 (en) 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
CN107427521B (zh) 2015-03-27 2021-08-03 达纳-法伯癌症研究所股份有限公司 细胞周期蛋白依赖性激酶的抑制剂
WO2016201370A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
EP4019515A1 (en) 2015-09-09 2022-06-29 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
WO2017133664A1 (en) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Bicyclic pyridine and pyrimidine derivatives and their use in the treatment， amelioration or prevention of influenza
WO2017133658A1 (en) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh 4, 7-diazaindole and 4, 7-diazaindazole derivatives and their use in the treatment, amelioration or prevention of influenza
WO2018232235A1 (en) 2017-06-16 2018-12-20 Beta Pharma, Inc. Pharmaceutical formulations of n-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and salts thereof
JOP20180094A1 (ar) 2017-10-18 2019-04-18 Hk Inno N Corp مركب حلقي غير متجانس كمثبط بروتين كيناز
JP7590185B2 (ja) 2018-06-25 2024-11-26 ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド Ｔａｉｒｅファミリーキナーゼインヒビターおよびそれらの使用
KR102195348B1 (ko) * 2018-11-15 2020-12-24 에이치케이이노엔 주식회사 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
EP3902542A4 (en) 2018-12-28 2022-09-07 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 and uses thereof
JP7772771B2 (ja) * 2020-07-14 2025-11-18 武漢朗来科技発展有限公司 Ｒｏｃｋ阻害剤及びその製造方法と用途
CN113563310B (zh) * 2021-06-25 2022-10-11 浙江工业大学 一种4-(1-甲基吲哚-3-基)嘧啶类衍生物及其应用
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors
CN114790174B (zh) * 2022-04-14 2023-09-29 淮阴工学院 一种连续合成1h-吲唑类化合物的方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4788195A (en) * 1986-01-13 1988-11-29 American Cyanamid Company 4,5,6-substituted-N-(substituted-phenyl)-2-pyrimidinamines
DE60006541D1 (de) 1999-06-30 2003-12-18 Merck & Co Inc Src-kinase hemmende verbindungen
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
WO2001060816A1 (en) * 2000-02-17 2001-08-23 Amgen Inc. Kinase inhibitors
RU2277911C2 (ru) * 2000-02-25 2006-06-20 Ф.Хоффманн-Ля Рош Аг Модуляторы аденозиновых рецепторов
GB0103926D0 (en) * 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
DE60230160D1 (de) 2001-02-20 2009-01-15 Astrazeneca Ab 2-arylaminopyrimidine zur behandlung von mit gsk3 in zusammenhang stehenden erkrankungen
UA75392C2 (en) * 2001-02-23 2006-04-17 Merck & Co Inc N-substituted non-aryl heterocyclic antagonists nmda/nr2b
WO2002102783A1 (en) * 2001-06-19 2002-12-27 Merck & Co., Inc. Tyrosine kinase inhibitors
EP1463730B1 (en) * 2001-12-17 2006-04-19 SmithKline Beecham Corporation Pyrazolopyridazine derivatives
TW200302722A (en) 2002-02-13 2003-08-16 Astrazeneca Ab Therapeutic agents
JP4570955B2 (ja) 2002-07-09 2010-10-27 バーテクス ファーマスーティカルズ インコーポレイテッド プロテインキナーゼ阻害活性を持つイミダゾール類
TW200528101A (en) 2004-02-03 2005-09-01 Astrazeneca Ab Chemical compounds
WO2006050076A1 (en) * 2004-10-29 2006-05-11 Janssen Pharmaceutica, N.V. Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
BRPI0610828A2 (pt) * 2005-05-16 2010-07-27 Irm Llc compostos e composições como inibidores de proteìna quinase
DE102006012617A1 (de) * 2006-03-20 2007-09-27 Merck Patent Gmbh 4-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate
JP5325783B2 (ja) 2006-09-08 2013-10-23 エフ．ホフマン−ラ ロシュ アーゲー ベンゾトリアゾールキナーゼモジュレーター
US8202876B2 (en) 2006-10-02 2012-06-19 Irm Llc Compounds and compositions as protein kinase inhibitors
WO2008045484A1 (en) 2006-10-10 2008-04-17 Amgen Inc. N-aryl pyrazole compounds for use against diabetes
CN102256965A (zh) * 2008-12-19 2011-11-23 霍夫曼-拉罗奇有限公司 嘧啶-2-基氨基衍生物和它们治疗炎症的用途

Also Published As

Publication number Publication date
EP2102194A1 (en) 2009-09-23
KR20090075877A (ko) 2009-07-09
JP2010511655A (ja) 2010-04-15
MX2009005508A (es) 2009-06-03
CN101547917A (zh) 2009-09-30
RU2009125672A (ru) 2011-01-20
RU2493155C2 (ru) 2013-09-20
WO2008068171A1 (en) 2008-06-12
CL2007003502A1 (es) 2008-06-27
AR064133A1 (es) 2009-03-11
US20080146565A1 (en) 2008-06-19
TW200831101A (en) 2008-08-01
CA2670375A1 (en) 2008-06-12
US8399462B2 (en) 2013-03-19
KR101152162B1 (ko) 2012-07-10
ZA200903495B (en) 2010-04-28
JP5179509B2 (ja) 2013-04-10
NO20091942L (no) 2009-07-07
BRPI0720003A2 (pt) 2018-09-18
WO2008068171A9 (en) 2009-07-16
AU2007328981A1 (en) 2008-06-12
IL198543A0 (en) 2010-02-17
AU2007328981B2 (en) 2013-07-11

Similar Documents

Publication Publication Date Title
PE20081507A1 (es) Derivados de pirimidina como moduladores de jnk
PE20091236A1 (es) Derivados de pirimidina como immunomoduladores de tlr7
PE20081262A1 (es) Derivados de fenilo como moduladores de cinasas y composiciones
PE20110150A1 (es) Amidofenoxiindazoles como inhibidores de c-met
ES2477940T3 (es) Imidazoles condensados y composiciones que los incluyen para el tratamiento de enfermedades parasitarias tales como por ejemplo malaria
PE20091734A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
PE20091033A1 (es) Derivados de nicotinamida como agentes anticancerosos y su preparacion
PE20090694A1 (es) Compuestos moduladores de sirtuinas
PE20110547A1 (es) Compuestos de isoindolina con actividad anticancerigena
PE20130405A1 (es) Compuestos de pirazol-4-il-heterociclil-carboxamida y metodos de uso
PE20090552A1 (es) Compuestos de pirimidina hidrazida como inhibidores de pgds
PE20080074A1 (es) Derivados de amida como agentes inhibidores de la quinasa c-fms
PL2130527T3 (pl) Kompozycje oftalmiczne z amfoterycznym środkiem powierzchniowo czynnym i kwasem hialuronowym
PE20071236A1 (es) Derivados de piperidinilo como moduladores de la actividad del receptor de quimiocina
PE20141404A1 (es) Derivados de tieno[3,2-d]pirimidina que tienen actividad inhibidora por las quinasas de las proteinas
PE20070136A1 (es) COMPUESTOS DERIVADOS DE N-(PIRIDIN-2-IL)-SULFONAMIDA COMO INHIBIDORES DE LA ENZIMA 11-beta-HIDROXIESTEROIDE DESHIDROGENASA HUMANA TIPO 1
PE20121335A1 (es) Compuestos derivados de amida como inhibidores de raf cinasas
AR072904A1 (es) Compuestos de fenilamino-isonicotinamida y composiciones farmaceuticas que los contienen
PE20151981A1 (es) Pontenciador de inhibidores del homologo de zeste
PE20091065A1 (es) Derivados bis-(sulfonilamino) en terapia 066
PE20091816A1 (es) Inhibidores de bace
PE20142340A1 (es) Inhibidores de bromodominios
CR10682A (es) Compuestos de tiazol pirazolopirimidina
PE20040155A1 (es) Derivados aminoinazoles, procedimiento de preparacion e intermedios de este procedimiento a titulo de medicamentos y composiciones farmaceuticas que los contienen
GEP20156348B (en) Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed